EZH2 and central nervous system cancer: EZH2 appears to be particularly important in high‐grade gliomas where Polycomb repressive complexes promote disease progression and therapy resistance by sustaining cancer cell self‐renewal and favouring cellular plasticity 24, 25, 26, 27, 28, 29.